All In Biotech

Drug Trial Radar · NCT06828120

A Randomized, Safety and Efficacy Study of Taneasy 600mg Granules and Fluimucil 600mg Granules in COPD Subjects

Last checked: Nov 20, 2026Latest source record: Sep 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

Feb 20, 2025

Primary completion

Sep 3, 2025

Study completion Sep 17, 2025

Sponsor

Lead sponsor
Bun Yao Biotechnology Co., LtdIndustry
Sponsor type
Industry
Collaborators
Clinny biotech limited; Taipei Veterans General Hospital, Taiwan
First posted
Feb 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and efficacy of Taneasy 600mg granules and Fluimucil 600mg granules administered twice daily for 14 days in treatment of COPD Disease.

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)

Interventions

  • Taneasy 600mg granulesDrug

    Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, plumonary emphysema,mucoviscidosis and bronchiectasis.

  • Fluimucil 600mg granulesDrug

    Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, plumonary emphysema,mucoviscidosis and bronchiectasis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and efficacy of Taneasy 600mg granules and Fluimucil 600MG granules administered twice daily for 14 days in treatment of COPD Disease.Time frame: one month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Taipei Veterans General Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.